中国药房2018，Vol.29Issue(10)：1377-1380,4.DOI:10.6039/j.issn.1001-0408.2018.10.20
三胶扶正合剂联合紫杉醇、奈达铂同步放化疗治疗局部晚期非小细胞肺癌的临床观察
Clinical Observation of Sanjiao Fuzheng Mixture Combined with Concurrent Chemoradiotherapy of Paclitaxel and Nedaplatin in the Treatment of Local Advanced Non-small Cell Lung Cancer
摘要
Abstract
OBJECTIVE:To observe the efficacy and safety of Sanjiao fuzheng mixture combined with concurrent chemoradiotherapy of paclitaxel and nedaplatin in the treatment of local advanced non-small cell lung cancer (NSCLC). METHODS:A total of 68 patients with local advanced NSCLC selected from our hospital during Jan. 2015 to Jan. 2017 were divided into control group and observation group according to random number table,with 34 cases in each group. Control group was given Paclitaxel injection 135 mg/m2 intravenously,d1+Nedaplatin for injection 75 mg/m2 intravenously,d3,21 d as a treatment course,for 2 courses;routine fractionated intensity modulated radiation therapy,2 Gy each time,5 times a week,60-70 Gy in total;given 2 cycles of primary chemotherapy continuously after radiotherapy. Observation group was additionally given Sanjiao fuzheng mixture 250 mL/d,divided into 3 times,till the end of treatment,on the basis of control group. Clinical efficacies were observed in 2 groups. The levels of nutritional indexes (BMI,PAB,ALB,Hb) and tumor markers (SCC-Ag,CEA,TK1, CYFRA21-10) before and after treatment were observed. The occurrence of ADR were recorded. RESULTS:There was no statistical significance in the total effective rate between 2 groups (observation group 82.35％ vs. control group 73.53％)(P>0.05). After treatment,the levels of BMI,PAB,ALB and Hb in 2 groups were significantly lower than before treatment,but the observation group was significantly higher than the control group. The levels of SCC-Ag,CEA,TK1 and CYFRA21-1 in 2 groups were significantly lower than before treatment,and the observation group was significantly lower than the control group,with statistical significance (P<0.05). The incidence of Ⅲ-Ⅳ degree aleucocytosis,Ⅰ-Ⅱ degree hemoglobin reduction and thrombocytopenia in observation group were significantly lower than control group, with statistical significance (P<0.05). CONCLUSIONS:The efficacy of Sanjiao fuzheng mixture combined with concurrent chemoradiotherapy of paclitaxel and nedaplatin is similar to that of concurrent chemoradiotherapy of paclitaxel and nedaplatin for localadvanced NSCLC,which can improve nutritional status significantly,and reduce the incidence of ADR.关键词
同步放化疗/紫杉醇/奈达铂/三胶扶正合剂/局部晚期非小细胞肺癌/疗效/安全性Key words
Concurrent chemoradiotherapy/Paclitaxel/Nedaplatin/Sanjiao fuzheng mixture/Local advanced non-small cell lung cancer/Clinical efficacy/Safety分类
医药卫生引用本文复制引用
冉毅,李少林,夏冬梅,包中会,任洪波,蒋义,杨吉帆,黄碧有,姚岚,倪燕侠..三胶扶正合剂联合紫杉醇、奈达铂同步放化疗治疗局部晚期非小细胞肺癌的临床观察[J].中国药房,2018,29(10):1377-1380,4.基金项目
重庆市巴南区科委卫生科技项目(No.巴南科委发〔2016〕26号). （No.巴南科委发〔2016〕26号）
